Radiation therapy is a widely
used clinical approach for treatment of solid tumors; however, radiation
therapy can cause various adverse side effects.
Radiation sensitizers act in a number of ways to make cancer cells more
susceptible to death by radiation than the surrounding healthy cells. There is a present market need for an
effective and clinically viable radiation sensitizer that enhances radiation
effects and mitigates adverse side effects.
Similarly, enhancing the efficacy of chemotherapy and reducing its
adverse effects would be highly desirable.
Arsenic is a naturally occurring element that is
present in food, soil, and water. Environmental or occupational exposures to
arsenic are associated with both acute and chronic toxic effects in humans,
including increased incidence of skin, lung, liver, and urinary tract cancers. New studies at the University of New
Mexico show that arsenic, in low micromolar concentrations, robustly inhibits DNA repair, enhancing
the effects of radiation or chemotherapy in cells and animal models.
University of New Mexico
researchers have developed arsenic trioxide (ATO) as a radiation/chemotherapy
sensitizer to enhance the radiation/chemotherapy effect in cells. Researchers have demonstrated that arsenite
inhibits DNA damage repair through inhibition of PARP-1 activity.
STC has filed intellectual property on this exciting new technology and is currently exploring commercialization options. If you are interested in information about this or other technologies, please contact Arlene Mirabal at email@example.com or 505-272-7886.